AU2003302072A1 - Palonosetron for the treatment of chemotherapy-induced emesis - Google Patents

Palonosetron for the treatment of chemotherapy-induced emesis

Info

Publication number
AU2003302072A1
AU2003302072A1 AU2003302072A AU2003302072A AU2003302072A1 AU 2003302072 A1 AU2003302072 A1 AU 2003302072A1 AU 2003302072 A AU2003302072 A AU 2003302072A AU 2003302072 A AU2003302072 A AU 2003302072A AU 2003302072 A1 AU2003302072 A1 AU 2003302072A1
Authority
AU
Australia
Prior art keywords
palonosetron
chemotherapy
treatment
induced emesis
emesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003302072A
Other languages
English (en)
Inventor
Enrico Braglia
Riccardo Braglia
Sergio Cantoreggi
Alberto Macciocchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Healthcare SA
Original Assignee
Helsinn Healthcare SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003302072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare SA filed Critical Helsinn Healthcare SA
Publication of AU2003302072A1 publication Critical patent/AU2003302072A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
    • G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
    • G06F16/23—Updating
    • G06F16/2379—Updates performed during online database operations; commit processing

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Databases & Information Systems (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Theoretical Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Otolaryngology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003302072A 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis Abandoned AU2003302072A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42682902P 2002-11-15 2002-11-15
US60/426,829 2002-11-15
PCT/IB2003/005567 WO2004045615A1 (en) 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis

Publications (1)

Publication Number Publication Date
AU2003302072A1 true AU2003302072A1 (en) 2004-06-15

Family

ID=32326433

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003302072A Abandoned AU2003302072A1 (en) 2002-11-15 2003-11-06 Palonosetron for the treatment of chemotherapy-induced emesis

Country Status (6)

Country Link
US (2) US20060079545A1 (enExample)
JP (4) JP5690461B2 (enExample)
AU (1) AU2003302072A1 (enExample)
CA (1) CA2505990C (enExample)
DE (1) DE10393729T5 (enExample)
WO (1) WO2004045615A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003303956A1 (en) * 2002-11-05 2004-11-23 Smithkline Beecham Corporation Antibacterial agents
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
EA016455B1 (ru) * 2006-10-24 2012-05-30 Хелсинн Хелткэр С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
JP2010512333A (ja) * 2006-12-07 2010-04-22 ヘルシン ヘルスケア ソシエテ アノニム 塩酸パロノセトロンの結晶及び非晶質形
US20110118189A1 (en) * 2008-04-28 2011-05-19 Farr Stephen J Novel formulations for treatment of migraine
JP5547065B2 (ja) 2008-05-15 2014-07-09 久光製薬株式会社 パロノセトロンを含有する経皮吸収製剤
US20100048607A1 (en) * 2008-08-25 2010-02-25 Chandrashekhar Kocherlakota Formulations comprising palonosetron
EP2364138A2 (en) * 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
EP2499137A1 (en) 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
US20160206610A1 (en) * 2015-01-20 2016-07-21 Xoc Pharmaceuticals, Inc. Methods for treating and/or preventing emesis and/or nausea including acute and/or delayed nausea and/or acute emesis and/or delayed emesis
JP6642377B2 (ja) * 2016-10-25 2020-02-05 ニプロ株式会社 液体製剤、及び、パロノセトロンの安定性を向上する方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US807381A (en) * 1905-01-10 1905-12-12 Auto Stopper Company Means for securing stoppers for vessels in their caps.
US1796729A (en) * 1930-04-18 1931-03-17 Aluminum Co Of America Closure
US2069075A (en) * 1934-04-20 1937-01-26 United Dairies London Ltd Bottle or like container
US2113176A (en) * 1936-03-26 1938-04-05 Guardian Safety Seal Company Sealed receptacle
US3314564A (en) * 1965-05-06 1967-04-18 West Co Container closure
US3601273A (en) * 1969-01-31 1971-08-24 Aluminum Co Of America Pilferproof closure with vertical weakening lines
DE2315962A1 (de) * 1972-04-05 1973-10-18 Metal Closures Ltd Verschlusskappenrohling fuer flaschen od. dgl.
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
AU642178B2 (en) * 1989-11-28 1993-10-14 Roche Palo Alto Llc New tricyclic compounds
GB2277749B (en) * 1993-05-08 1996-12-04 Ciba Geigy Ag Fluorescent whitening of paper
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
US20030127420A1 (en) * 2002-01-09 2003-07-10 Klaus Schumacher Dual bottle closure
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride

Also Published As

Publication number Publication date
JP2012131811A (ja) 2012-07-12
JP2016199588A (ja) 2016-12-01
CA2505990C (en) 2009-05-19
JP2006508977A (ja) 2006-03-16
DE10393729T5 (de) 2005-10-13
JP6342960B2 (ja) 2018-06-13
JP5893950B2 (ja) 2016-03-23
CA2505990A1 (en) 2004-06-03
JP2015143266A (ja) 2015-08-06
US20060079545A1 (en) 2006-04-13
JP5690461B2 (ja) 2015-03-25
US20110178118A1 (en) 2011-07-21
WO2004045615A1 (en) 2004-06-03

Similar Documents

Publication Publication Date Title
AU2002348135A1 (en) Methods for the treatment of addiction
AU2003226168A1 (en) Fluorochemical treatment for silicon articles
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2002240359A1 (en) Pharmaceutical composition for the treatment of alopecia
AU2003258145A8 (en) Substituted phenylindoles for the treatment of hiv
AU2003241599A1 (en) Compositions and methods for the treatment of hemophilia a
AU2003224002A1 (en) Drugs for the arthritis treatment
IL165773A0 (en) Use of nefopam for the treatment of nausea or emesis
AU2003260778A1 (en) Treatment of pipes
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003233820A1 (en) Method for the treatment of starch
AU2003291886A1 (en) Thiophenederivatives for the treatment of flavivirus infections
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003258983A1 (en) Combinations for the treatment of fungal infections
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
AU2003270202A1 (en) Pharmaceutical compositions increasing camp useful for the treatment of cancers
AU2003266960A1 (en) Composition for the treatment of pain, especially for the treatment of articular pain
AU2003240174A1 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003260723A1 (en) Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
AU2003281158A1 (en) The treatment of emesis
AU2003281836A1 (en) Implant for the treatment of presbyopia
AU2003212888A1 (en) Combinations for the treatment of fungal infections
AU2003289889A1 (en) Methods for the treatment of alzheimers disease and compositions therefore

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase